Department of Urban-Global Public Health, Rutgers School of Public Health, Newark, NJ.
Positive Impact Health Centers, Atlanta, GA.
J Acquir Immune Defic Syndr. 2023 May 1;93(1):55-63. doi: 10.1097/QAI.0000000000003167.
This uncontrolled pilot study examined the feasibility, acceptability, and preliminary HIV and psychological health effects of iTHRIVE 365, a multicomponent intervention designed by and for Black same gender loving men (SGLM) to promote: health knowledge and motivation, Black SGLM social support, affirming health care, and housing and other economic resources.
We conducted a 14-day daily diary study with 32 Black SGLM living with HIV connected to THRIVE SS in Atlanta, GA. Daily surveys assessed intervention engagement, antiretroviral medication (ART) use, depressive symptoms, anxiety symptoms, and emotion regulation difficulties. App paradata (ie, process data detailing app usage) assessed amount of intervention engagement via page access. Participants began receiving access to the intervention on day 7. After the 14-day daily diary period, participants responded to follow-up items on the user-friendliness, usefulness, helpfulness, and whether they would recommend iTHRIVE 365 to others. Chi-square analyses examined associations between intervention engagement and ART use, and dynamic structural equation modelling assessed longitudinal associations from intervention engagement to next-day psychological health. This intervention trial is registered on ClinicalTrials.gov (NCT05376397).
On average, participants engaged with iTHRIVE 365 over once every other day and accessed intervention pages 4.65 times per day. Among participants who engaged with the intervention, 78% reported it was helpful to extremely helpful, 83% reported it was moderately to extremely useful, and 88% reported it was user-friendly and they would recommend it to others. On intervention engagement days, participants had higher odds of ART use, χ 2 (1) = 4.09, P = 0.04, than intervention nonengagement days. On days after intervention engagement, participants showed non-null decreases in depressive symptoms (τ = -0.14; 95% CI : = [-0.23, -0.05]) and emotion regulation difficulties (τ = -0.16; 95% CI : = [-0.24, -0.02]).
Findings suggest iTHRIVE 365 is feasible, acceptable, and positively affects daily ART use, depressive symptoms, and emotion regulation difficulties.
本非对照性初步研究旨在检验 iTHRIVE 365 的可行性、可接受性，以及对艾滋病毒和心理健康的初步影响。iTHRIVE 365 是一项多组分干预措施，由黑人男同性恋者设计并面向他们，以促进以下方面：健康知识和动机、黑人男同性恋者的社会支持、支持性保健以及住房和其他经济资源。
我们在佐治亚州亚特兰大市与 THRIVE SS 合作的 32 名感染艾滋病毒的黑人男同性恋者中开展了一项为期 14 天的每日日记研究。每日调查评估了干预措施的参与度、抗逆转录病毒药物（ART）的使用、抑郁症状、焦虑症状和情绪调节困难。应用程序数据（即详细记录应用程序使用情况的过程数据）通过页面访问评估了干预措施参与度的多少。参与者在第 7 天开始获得干预措施的访问权限。在 14 天的每日日记期结束后，参与者回答了关于用户友好性、有用性、帮助性以及他们是否会向他人推荐 iTHRIVE 365 的后续问题。卡方分析检验了干预措施参与度与 ART 使用之间的关联，动态结构方程模型评估了从干预措施参与度到下一天心理健康的纵向关联。这项干预试验已在 ClinicalTrials.gov （NCT05376397）注册。
平均而言，参与者每隔一天就会使用 iTHRIVE 365 一次以上，每天访问干预措施页面 4.65 次。在参与干预措施的参与者中，78%的人认为它非常有帮助，83%的人认为它非常有用，88%的人认为它用户友好，他们会向其他人推荐它。在干预措施参与日，参与者使用抗逆转录病毒药物的几率更高，χ 2 （1）= 4.09，P = 0.04，而在干预措施非参与日则更低。在干预措施参与日之后的日子里，参与者的抑郁症状（τ=-0.14；95%置信区间：[-0.23，-0.05]）和情绪调节困难（τ=-0.16；95%置信区间：[-0.24，-0.02]）均出现非零下降。
研究结果表明，iTHRIVE 365 具有可行性、可接受性，并能积极影响每日抗逆转录病毒药物的使用、抑郁症状和情绪调节困难。
